View clinical trials related to CNS Lesion.
Filter by:This Phase 2 trial will assess the safety, tolerability, efficacy, imaging pharmacodynamics, and pharmacokinetics of RVP-001, a novel manganese-based MRI contrast agent, at three escalating dose levels. RVP-001 will be administered as a single IV bolus to subjects with known gadolinium-enhancing central nervous system (CNS) lesions (for example stable brain tumor or multiple sclerosis) who have recently had a gadolinium-based contrast agent (GBCA)-enhanced MRI of the brain.
This trial conducted in Japan includes 2 different cohorts of patients: adult patients and pediatric patients with two different designs. - The cohort of adult patients has a prospective, multi-center, randomized, double-blind, controlled, and cross-over design. - The cohort of pediatric patients has a prospective, multi-center, non-randomized, open-label and single arm design. Primary objective to demonstrate the non-inferiority of gadopiclenol-enhanced MRI at 0.05 mmol/kg body weight (BW) compared to gadobutrol-enhanced MRI at 0.1 mmol/kg BW in terms of lesion visualization is applicable for adult patients referred for contrast-enhanced MRI of Central Nervous System (CNS) or Body regions.